Structure Therapeutics (NASDAQ: GPCR ) stock is surging today, up 60% after the biotech company reported promising results of its mid-stage trials for its weight loss pills. Indeed, after 12 weeks, patients on the treatment lost an average of 6.2% of their weight, with one-third of patients losing more than 10% of their weight.
Structure Therapeutics stock roses sharply Monday after the biotech company delivered "compelling" results for its weight-loss drug.
Structure Therapeutics Inc.'s American depositary receipts GPCR, +1.30% gained more than 6% premarket on Monday after the company said its experimental weight-loss pill achieved its aims in a clinical trial.